Sleep medication for insomnia in Parkinson's disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a sleep medication called lemborexant in people with Parkinson's disease who also have insomnia. The goal is to see if it improves both sleep and movement symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years of age or older.
- You have been diagnosed with Parkinson's disease and are at Hoehn & Yahr stage 1 to 4 (mild to moderate).
- You have had Parkinson's for at least 2 years and your medication is stable (no changes in the last 4 weeks).
- You have insomnia (trouble sleeping) that is moderate to severe (score of 15 or more on the Insomnia Severity Index).
- You do not have untreated sleep apnea, severe mental health conditions, or significant memory problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a medication that blocks brain chemicals involved in wakefulness can help reduce markers of nerve damage in people with insomnia. It is for adults aged 40–65 with chronic insomnia, and it aims to see if improving sleep may protect brain health.
This study tests if lemborexant, a sleep medication, can help people with both a mental health condition and insomnia. You would take the medicine as prescribed and complete questionnaires over 2 months.
This trial tests if the sleep medication lemborexant can help people with early-stage dementia who also have insomnia. It uses an N-of-1 design, meaning it will look at how you personally respond to the drug compared to a placebo.
This study tests a new sleep medicine called Dimdazenil for people with Parkinson's disease who also have trouble sleeping. The goal is to see if it helps improve sleep without making Parkinson's symptoms worse.
This trial tests if a simple, non-invasive arm cuff treatment can improve sleep and other non-motor symptoms in people with early Parkinson's disease. It involves using a blood pressure-like cuff on your arm to briefly restrict blood flow, then release it, hoping to train your body's protective systems.
This study tests if the sleep medication lemborexant can help people with opioid use disorder who also have chronic insomnia. Participants must already be taking buprenorphine (Suboxone) for at least 4 weeks. The goal is to see if better sleep improves mood and reduces opioid use.
Hear when a new Parkinson’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.